OncoMatch/Clinical Trials/NCT04969731
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
Is NCT04969731 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Immuncell-LC and Gemcitabine for pancreatic ductal adenocarcinoma.
Treatment: Immuncell-LC · Gemcitabine — PURPOSE: This phase III clinical trial evaluates the efficacy and safety of adjuvant Immuncell-LC therapy combined with gemcitabine versus adjuvant gemcitabine single therapy after R0 or R1 resection in patients with pancreatic ductal adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: surgery — curative intent (R0 or R1 resection)
Participants have undergone a radical full resection (R0) or boundary resection (R1) operation and has elapsed at least two weeks after the resection based on the baseline, up to 12 weeks.
Cannot have received: anticancer therapy
Exception: Neo-adjuvant therapy for pancreatic cancer is allowed
Received anticancer therapy including chemotherapy, biological therapy, immunotherapy, hormone therapy, radiation therapy, and other anti-cancer treatments. Note: Neo-adjuvant therapy for pancreatic cancer is allowed.
Cannot have received: Immuncell-LC, Natural Killer (NK) cell therapy or other cell therapy drugs
Received Immuncell-LC, Natural Killer (NK) cell therapy or other cell therapy drugs within three years prior to screening.
Lab requirements
Blood counts
Absolute neutrophil count 3E= 1,500/b5L; Hemoglobin level 3E= 9 g/dL; Platelet count 3E= 100,000/b5L
Kidney function
BUN, serum creatinine 3C= 1.5 d7 institutional upper limit of normal (ULN)
Liver function
AST, ALT 3C= 2.5 d7 institutional upper limit of normal (ULN)
Adequate organ and marrow function at the screening and baseline as defined below: Absolute neutrophil count 3E= 1,500/b5L; Hemoglobin level 3E= 9 g/dL; Platelet count 3E= 100,000/b5L; BUN, serum creatinine 3C= 1.5 d7 institutional upper limit of normal (ULN); AST, ALT 3C= 2.5 d7 institutional upper limit of normal (ULN); PT (INR), activated partial thromboplastin time (aPTT) 3C= 1.5 d7 institutional upper limit of normal (ULN)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify